Come join others currently navigating treatment in our weekly Virtual Support Groups! See times and register here.
We've made it easier for you to connect! Fill out your NEW profile.
Verzenio + fulvestrant increased OS in ER+/HER2+ MBC
olma61
Posts: 1,042
I guess this could eventually mean a new first line for estrogen positive HER2+ patients. This was just a Phase 2 trial so I suppose there has to be a Phase 3 before it would become common in clinical use. Looks like they didn’t include Perjeta (pertuzumab) in this protocol, either.
CONCLUSION:
In this phase II trial, abemaciclib + trastuzumab +/- fulvestrant numerically improved median OS in women with HR+, HER2+ ABC compared to SOC chemotherapy + trastuzumab.
LINK: Practice Update - Metastatic Breast Cancer Newsletter
https://www.practiceupdate.com/c/158894/67/13/?elsca1=emc_enews_weekinreview&elsca2=email&elsca3=practiceupdate_metastaticbreastcancer&elsca4=metastaticbreastcancer&elsca5=newsletter&rid=NDcyNTI4MzY5MTA0S0&lid=20849614
Tagged:
0
Categories
Join Us on Zoom: Upcoming virtual support groups. Read more...
Share more about you! Fill out your NEW profile.